Laboratory of Molecular Medicine and Neuroscience, Molecular Medicine and Virology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 Room 3B14 MSC 1295, Bethesda, MD 20892-1296, USA.
J Neuroimmune Pharmacol. 2010 Sep;5(3):404-17. doi: 10.1007/s11481-010-9203-1. Epub 2010 Apr 17.
Progressive multifocal leukoencephalopathy (PML) is a growing concern for patients undergoing immune modulatory therapies for treatment of autoimmune diseases such as multiple sclerosis. Currently, there are no drugs approved for the treatment of PML that have been demonstrated in the patient to effectively and reproducibly alter the course of disease progression. The human polyoma virus JC is the causative agent of PML. JC virus (JCV) dissemination is tightly controlled by regulation of viral gene expression from the promoter by cellular transcription factors expressed in cells permissive for infection. JCV infection likely occurs during childhood, and latent virus containing PML-associated promoter sequences is maintained in lymphoid cells within the bone marrow. Because development of PML is tightly linked to suppression and or modulation of the immune system as in development of hematological malignancies, AIDS, and monoclonal antibody treatments, further scrutiny of the course of JCV infection in immune cells will be essential to our understanding of development of PML and identification of new therapeutic targets.
进行免疫调节治疗自身免疫性疾病（如多发性硬化症）的患者中，进行性多灶性白质脑病（PML）日益受到关注。目前，尚无经证实可有效且可重复改变疾病进展过程的药物获批用于治疗 PML。人类多瘤病毒 JC 是 PML 的致病因子。JC 病毒（JCV）的传播受到细胞转录因子对感染细胞中启动子的病毒基因表达的调控的严格控制。JCV 感染可能发生在儿童时期，含有 PML 相关启动子序列的潜伏病毒存在于骨髓中的淋巴细胞中。由于 PML 的发展与免疫系统的抑制和/或调节密切相关，如血液系统恶性肿瘤、艾滋病和单克隆抗体治疗，因此对免疫细胞中 JCV 感染过程的进一步研究对于我们了解 PML 的发展和确定新的治疗靶点至关重要。
